Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Logan C. Tyler"'
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3259-3265 (2023)
Abstract Background The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients tr
Externí odkaz:
https://doaj.org/article/b4a49be5552c4d6ea20d58cdd6f1cf4d
Autor:
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele
Publikováno v:
Thoracic Cancer, Vol 13, Iss 21, Pp 3032-3041 (2022)
Abstract Background ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving byp
Externí odkaz:
https://doaj.org/article/69b9447303ff45faa281860090224996
Publikováno v:
Cancer Research. 82:1102-1102
ALK/ROS1 TKIs have significantly improved outcomes for patients with ALK/ROS1+ lung adenocarcinoma. However, drug resistance inevitably develops, leading to disease progression. Approximately 1/3 of patients resistant to ROS1 TKIs demonstrate on-targ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1caadb43e18cde696f49af7144f4cf58
https://doi.org/10.1158/1538-7445.am2022-1102
https://doi.org/10.1158/1538-7445.am2022-1102
Autor:
Logan C. Tyler, Anh T. Le, Hala Nijmeh, Liming Bao, Timothy R. Wilson, Brian Simmons, David Chen, Robert C. Doebele
Publikováno v:
Cancer Research. 82:1103-1103
ROS1 TKIs entrectinib and crizotinib have significantly improved outcomes for ROS1+ lung adenocarcinoma patients. However, drug resistance inevitably develops, leading to disease progression. Approximately 1/3 of patients resistant to ROS1 TKIs demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74ac853d28743da1feab2fc61d1899bb
https://doi.org/10.1158/1538-7445.am2022-1103
https://doi.org/10.1158/1538-7445.am2022-1103
Autor:
Mary C.M. Weiser-Evans, Emily K. Kleczko, Bonnie L. Bullock, Peter C. Harris, Katharina Hopp, Christopher Altmann, Seth B. Furgeson, Raphael A. Nemenoff, Logan C. Tyler, Michel Chonchol, Eric T. Clambey, Berenice Gitomer, Makoto Miyazaki, Kenneth H. Marsh
Publikováno v:
Kidney International. 94:1127-1140
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent inherited nephropathy. To date, therapies alleviating the disease have largely focused on targeting abnormalities in renal epithelial cell signaling. ADPKD has many hallmarks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a515819e4cfd3eeb246e0d3ebc31e58
https://doi.org/10.1016/j.kint.2018.06.025
https://doi.org/10.1016/j.kint.2018.06.025
Autor:
Logan C. Tyler, Anh T. Le, Hala Nijmeh, Liming Bao, Kristen Turner, Jason Christianson, Robert C. Doebele
Publikováno v:
Molecular Cancer Therapeutics. 20:P076-P076
ROS1 tyrosine kinase inhibitors (TKIs) entrectinib and crizotinib have significantly improved outcomes for patients with ROS1 gene fusion positive (ROS1+) lung adenocarcinoma. However, drug resistance inevitably develops, leading to disease progressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6003c2914d4723a4c6356b83d8acad70
https://doi.org/10.1158/1535-7163.targ-21-p076
https://doi.org/10.1158/1535-7163.targ-21-p076
Publikováno v:
Cancer Research. 80:3003-3003
ROS1 gene fusions are predominantly found in non-small cell lung cancer (NSCLC), and ROS1 gene fusion-positive (ROS1+) tumors comprise 1-2% of all diagnosed lung adenocarcinomas. Currently, there are two ROS1 tyrosine kinase inhibitors (TKIs) which a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::615d1422ec12e061adf63298effc1597
https://doi.org/10.1158/1538-7445.am2020-3003
https://doi.org/10.1158/1538-7445.am2020-3003
Autor:
Emily K, Kleczko, Kenneth H, Marsh, Logan C, Tyler, Seth B, Furgeson, Bonnie L, Bullock, Christopher J, Altmann, Makoto, Miyazaki, Berenice Y, Gitomer, Peter C, Harris, Mary C M, Weiser-Evans, Michel B, Chonchol, Eric T, Clambey, Raphael A, Nemenoff, Katharina, Hopp
Publikováno v:
Kidney international
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent inherited nephropathy. To date, therapies alleviating the disease have largely focused on targeting abnormalities in renal epithelial cell signaling. ADPKD has many hallmarks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::68e542528bca782b16f4b12730208456
https://pubmed.ncbi.nlm.nih.gov/30249452
https://pubmed.ncbi.nlm.nih.gov/30249452